Patent ID: 8263344
Filing Date: 2012-09-11
Classification: G01N

Abstract:
1. An in vitro or ex vivo method for determining the susceptibility of a tumour cell to a cancer treatment selected from chemotherapy, radiotherapy, hormonotherapy, immunotherapy or specific kinase inhibitor-based therapy, the method comprising determining whether a tumour cell that has been previously treated by a cancer treatment selected from chemotherapy, radiotherapy, hormonotherapy, immunotherapy or specific kinase inhibitor-based therapy expresses a functional CRT, KDEL receptor and/or ERp57 on its surface, the presence of a functional CRT being indicative of the susceptibility of the tumour cell to a cancer treatment effected by immune cells; the presence of a functional KDEL receptor and/or of a functional ERp57 being indicative of the susceptibility of the tumour cell which has been previously treated by the cancer treatment selected from chemotherapy, radiotherapy, hormonotherapy, immunotherapy or specific kinase inhibitor-based therapy, to a cancer treatment effected by immune cells; and the absence of CRT being indicative of the non-susceptibility of the tumour cell which has been previously treated by the cancer treatment selected from chemotherapy, radiotherapy, hormonotherapy, immunotherapy or specific kinase inhibitor-based therapy, to a cancer treatment effected by immune cells.